Purpose: This research determines the effect of sodium
lauryl sulfate
(SLS) as a surfactant, croscarmellose sodium (CS) as a disintegrating
agent, and SLS–CS combinations on 2-((3-(chloromethyl)benzoyl)oxy)benzoic
acid (3CH
2
Cl) (log
P
= 3.73) tablet formulations.
In addition, this study aims to determine the optimum of the 3CH
2
Cl tablet formula. Methods: The tablets are manufactured through
direct compression according to the simplex lattice design. The optimal
SLS and CS concentration was determined in vitro using linear and
quadratic models to achieve better tablet disintegration and dissolution.
Results: The same linear and quadratic coefficient profiles of SLS
and CS indicate that the combined coefficient of SLS–CS with
a quadratic model can be used to predict the effect of the SLS–CS
combination. Based on the linear model coefficients, SLS and CS increase
the value of flow time (9.35; 7.65), Carr index (26.17; 21.17), hardness
(9.84; 7.44), friability (0.38; 0.31), disintegrating time (5.74;
2.62), and drug release (84.28; 58.65). The quadratic model coefficient
shows that SLS–CS combinations increase flow time (0.60), Carr
index (2.00), hardness (1.00), and disintegrating time (1.04). Meanwhile,
they decrease friability (−0.02) and drug release (−9.10).
Conclusions: SLS, CS, and SLS–CS combinations affect the quality
of tablet mass and tablets. The optimum tablet formula was 3CH
2
Cl (300 mg), Ne (9.38%), SLS (0.92%), CS (2.33%), MCC (5%),
and SDL (ad 800 mg). 3CH
2
Cl has analgesic activity despite
the presence of tablet excipients. The 3CH
2
Cl tablet is
an innovative formulation and a new alternative for future analgesic
drugs.